Vienna Austria, May 15, 2013 – Hookipa Biotech AG, today announced that the company's Chief
Executive Officer, Dr. Katherine Cohen, will provide an overview of the company’s technologies and
programs at the BIO Equity Europe 2013 (Stockholm, Sweden, May 22-23; presentation on Thursday,
May 23, at 10:00 a.m. CET).
About Hookipa Biotech
Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative
prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology.
The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the
prevention and treatment of multiple infectious diseases and cancer. The platform is one of the most
promising new technologies for next generation vaccines due to its ability to stimulate both potent Bcell
and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models.
Unlike other vectors, Vaxwave® vaccines can be administered repeatedly to boost the immune
In October 2011, Hookipa raised € 7 million from internationally renowned venture capital investors,
Sofinnova Partners and Forbion Capital Partners. The company currently focuses on the development
of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and
build a robust product pipeline.
Dr. Katherine Cohen
Chief Executive Officer
Hookipa Biotech AG
1030 Vienna, Austria
Phone: +43 1 890 63 60
Fax: +43 1 890 63 60 399